Pharmacogenetic Information in Clinical Guidelines: The European Perspective
| Autor: | Swen, J.J., Nijenhuis, M., Rhenen, M. van, Boer-Veger, N.J. de, Buunk, A.M., Houwink, E.J.F., Mulder, H., Rongen, G.A., Schaik, R.H.N. van, Weide, J. van der, Wilffert, B., Deneer, V.H.M., Guchelaar, H.J., Royal Dutch Pharmacists Assoc KNMP |
|---|---|
| Přispěvatelé: | Clinical Chemistry |
| Rok vydání: | 2018 |
| Předmět: |
DECISION-SUPPORT
medicine.medical_specialty Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] MEDLINE Nationwide survey Pharmacists 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Physicians medicine IMPLEMENTATION Humans Pharmacology (medical) NETWORK PREEMPTIVE PHARMACOGENOMICS Pharmacology Polypharmacy Health professionals business.industry MEDICINE CYP2D6 Perspective (graphical) CONSORTIUM 3. Good health Pharmacogenomic Testing MODEL Europe Pharmacogenetics 030220 oncology & carcinogenesis Pharmacogenomics Family medicine NATIONWIDE SURVEY POLYPHARMACY business |
| Zdroj: | Clinical Pharmacology and Therapeutics, 103(5), 795-801 Clinical Pharmacology and Therapeutics, 103, 5, pp. 795-801 Clinical Pharmacology and Therapeutics, 103, 795-801 Clinical Pharmacology & Therapeutics, 103(5), 795-801. Wiley-Blackwell |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | Item does not contain fulltext Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).(1-3) In addition, patients are willing to consent to participate in PGx implementation studies.(4) However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.(1,2) Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.(5,6). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text